FR2174745A1 - Mixed veterinary vaccine - active against symptomatic and bacterial anthrax - Google Patents

Mixed veterinary vaccine - active against symptomatic and bacterial anthrax

Info

Publication number
FR2174745A1
FR2174745A1 FR7208255A FR7208255A FR2174745A1 FR 2174745 A1 FR2174745 A1 FR 2174745A1 FR 7208255 A FR7208255 A FR 7208255A FR 7208255 A FR7208255 A FR 7208255A FR 2174745 A1 FR2174745 A1 FR 2174745A1
Authority
FR
France
Prior art keywords
spores
vaccine
stage
anthracis
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7208255A
Other languages
French (fr)
Other versions
FR2174745B1 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INST ELEVAGE MED VET
Original Assignee
INST ELEVAGE MED VET
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INST ELEVAGE MED VET filed Critical INST ELEVAGE MED VET
Priority to FR7208255A priority Critical patent/FR2174745A1/en
Publication of FR2174745A1 publication Critical patent/FR2174745A1/en
Application granted granted Critical
Publication of FR2174745B1 publication Critical patent/FR2174745B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Mixed vaccine active against symptomatic anthrax and bacterial anthrax contg. spores of Bacillus anthracis and a culture of Clostridium chauvei inactivated by beta-propiolactone. The two active ingredients do not interfere with one another and a single injection will protect animals esp. cattle and sheep, against both diseases. The vaccine is prepd. as follow:- (a) B. anthracis is cultured and the spores diluted, depending on the dose required in the final vaccine. (b) A virulent form of C. chauvei is cultured in a known medium, inactivated with beta-pyropiolactone, and glycerin and potassium alum are added. (c) The spores from stage (a) are mixed with the vaccine obtd. from stage (b) in the relative proportions reqd. in the final vaccine. Usually the spores of B. anthracis are recovered in a mixture of glycerin and physiological water, the dilution being 1/120-1/160, corresponding to a titre of 10000 spores/ml. At least 0.25 pts. by vol. of beta-propiolactone per 100 pts. culture medium is added in stage (b). In stage (c) spores of B. anthracis are added to the vaccine so as to give a dilution of 1/120 to 1/160.
FR7208255A 1972-03-09 1972-03-09 Mixed veterinary vaccine - active against symptomatic and bacterial anthrax Granted FR2174745A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR7208255A FR2174745A1 (en) 1972-03-09 1972-03-09 Mixed veterinary vaccine - active against symptomatic and bacterial anthrax

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7208255A FR2174745A1 (en) 1972-03-09 1972-03-09 Mixed veterinary vaccine - active against symptomatic and bacterial anthrax

Publications (2)

Publication Number Publication Date
FR2174745A1 true FR2174745A1 (en) 1973-10-19
FR2174745B1 FR2174745B1 (en) 1975-03-14

Family

ID=9094929

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7208255A Granted FR2174745A1 (en) 1972-03-09 1972-03-09 Mixed veterinary vaccine - active against symptomatic and bacterial anthrax

Country Status (1)

Country Link
FR (1) FR2174745A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0460480A2 (en) * 1990-06-07 1991-12-11 Bayer Corporation Bacterin for the treatment of necrophorum diseases and a method for the production thereof
US20120251577A1 (en) * 2009-10-09 2012-10-04 Children's Medical Center Corporation Selectively disrupted whole-cell vaccine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NEANT *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0460480A2 (en) * 1990-06-07 1991-12-11 Bayer Corporation Bacterin for the treatment of necrophorum diseases and a method for the production thereof
EP0460480A3 (en) * 1990-06-07 1992-04-01 Mobay Corporation Bacterin for the treatment of necrophorum diseases and a method for the production thereof
AU644440B2 (en) * 1990-06-07 1993-12-09 Mobay Corporation Bacterin for the treatment of necrophorum diseases and a method for the production thereof
US6132709A (en) * 1990-06-07 2000-10-17 Bayer Corporation Bacterin for the treatment of necrophorum diseases and a method for the production thereof
US20120251577A1 (en) * 2009-10-09 2012-10-04 Children's Medical Center Corporation Selectively disrupted whole-cell vaccine
US9827299B2 (en) * 2009-10-09 2017-11-28 Children's Medical Center Corporation Selectively disrupted whole-cell vaccine

Also Published As

Publication number Publication date
FR2174745B1 (en) 1975-03-14

Similar Documents

Publication Publication Date Title
Smith et al. Occurrence of Clostridium difficile in infections of man
Ehrich et al. Production of Clostridium difficile antitoxin
Barnes The enzymes of lymphocytes and polymorphonuclear leucocytes
GB1300446A (en) Improvements in or relating to processes of producing compositions for controlling the bacterial flora in the intestines of human beings and animals
Hauschild et al. Clostridium perfringens type A infection of ligated intestinal loops in lambs
Taylor et al. The action of chloroform-killed suspensions of enteropathogenic Escherichia coli on ligated rabbit-gut segments
ES379641A1 (en) Ethylethyleneimine as an inactivation agent
FR2174745A1 (en) Mixed veterinary vaccine - active against symptomatic and bacterial anthrax
GB1404516A (en) Stabilization of microorganism cells lytic enzyme
US3422188A (en) Tissue culture hog cholera vaccine
GB981242A (en) Vaccines containing rare earth salts
Mitchell et al. Type C botulism: the agent, host susceptibility, and predisposing factors.
US3288680A (en) Stabilized clostridium perfringens beta-toxoid vaccine
Abe et al. Pathological changes produced by Fusobacterium necrophorum in experimental infection of mice
US5198214A (en) Anti-mastitis polyvalent vaccine, method of administration and method for production thereof
Chandler et al. Observations on the Mode of Action of Sulfanilamide in Vitro
Keppie et al. Early appearance of colonies of Brucella spp. on solid media containing erythritol
Dul et al. EF-4 bacteremia in a patient with hepatic carcinoid
Birkhaug Antigenic activity of fresh, frozen, and dry BCG vaccine
IE35321L (en) Treatment of pigs with bacterial endotoxins.
US3515708A (en) Protecting dogs against brucella canis bacteremia with killed brucella abortus strain 45/20 vaccine
US4762712A (en) Anti-mastitis polyvalent vaccine, method of administration and method for production thereof
Turner et al. THE EPSILON TOXIN OF CL. WELCHII TYPE D 2. MECHANISM OF ITS DEVELOPMENT IN CULTURES THROUGH THE ACTION OF EXTRACELLULAR PROTEINASES UPON ε PROTOTOXIN.
Garg et al. Cellular and humoral immune responses in sheep experimentally injected with killed and live Corynebacterium pseudotuberculosis
GB947912A (en) Braxy and/or blackleg and/or black disease vaccines

Legal Events

Date Code Title Description
ST Notification of lapse